Cargando…

Dynamics of Immune Checkpoints, Immune System, and BCG in the Treatment of Superficial Bladder Cancer

This paper aims to study the dynamics of immune suppressors/checkpoints, immune system, and BCG in the treatment of superficial bladder cancer. Programmed cell death protein-1 (PD-1), cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), and transforming growth factor-beta (TGF-β) are some of the exa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saad, Farouk Tijjani, Hincal, Evren, Kaymakamzade, Bilgen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684605/ https://www.ncbi.nlm.nih.gov/pubmed/29312460 http://dx.doi.org/10.1155/2017/3573082

Ejemplares similares

Dynamics of HIV/AIDS in Turkey from 1985 to 2016
por: Sayan, Murat, et al.
Publicado: (2017)

Global Stability Analysis of HIV+ Model
por: Saad, Farouk Tijjani, et al.
Publicado: (2018)

A fractional-order mathematical model for lung cancer incorporating integrated therapeutic approaches
por: Amilo, David, et al.
Publicado: (2023)

Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer
por: Lukacs, S., et al.
Publicado: (2013)

Role of urothelial cells in BCG immunotherapy for superficial bladder cancer
por: Bevers, R F M, et al.
Publicado: (2004)

Disseminated Mycobacterium bovis Infection Complicating Intravesical BCG Instillation for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder
por: Elzein, Fatehi, et al.
Publicado: (2016)

Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer
por: Bidnur, S., et al.
Publicado: (2016)

Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
por: Lopez-Beltran, Antonio, et al.
Publicado: (2021)

Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer
por: Buffen, Kathrin, et al.
Publicado: (2014)

Immune checkpoint blockade therapy for bladder cancer treatment
por: Kim, Jayoung
Publicado: (2016)

Systemic immunotherapy of superficial mouse bladder cancer with Avelumab (MSB0010718C), an anti-PD-L1 immune checkpoint inhibitor
por: Vandeveer, Amanda, et al.
Publicado: (2015)

Stability analysis of fractional order model on corona transmission dynamics
por: Hincal, Evren, et al.
Publicado: (2021)

Stability Analysis of Delayed Immune Response BCG Infection in Bladder Cancer Treatment Model by Stochastic Perturbations
por: Shaikhet, Leonid, et al.
Publicado: (2018)

Recognition and Treatment of BCG Failure in Bladder Cancer
por: Lightfoot, Andrew J., et al.
Publicado: (2011)

BCG in Bladder Cancer Immunotherapy
por: Jiang, Song, et al.
Publicado: (2022)

Systemic BCG‐osis following intravesical BCG instillation for bladder carcinoma
por: Liaw, Frank, et al.
Publicado: (2017)

The bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition
por: van Dorp, Jeroen, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors as a Treatment Option for Bladder Cancer: Current Evidence
por: Okobi, Tobechukwu J, et al.
Publicado: (2023)

Disseminated BCG: Complications of Intravesical Bladder Cancer Treatment
por: To, Uyen, et al.
Publicado: (2014)

Intravesical High Dose BCG Tokyo and Low Dose BCG Tokyo with GMCSF+IFN α Induce Systemic Immunity in a Murine Orthotopic Bladder Cancer Model
por: Tham, Sin Mun, et al.
Publicado: (2021)

Modelling the dynamics of toxicity associated with aflatoxins in foods and feeds
por: Kademi, Hafizu Ibrahim, et al.
Publicado: (2017)

Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day
por: Maiorano, Brigida Anna, et al.
Publicado: (2022)

Nano-BCG: A Promising Delivery System for Treatment of Human Bladder Cancer
por: Buss, Julieti Huch, et al.
Publicado: (2018)

In vitro Evidence of Human Immune Responsiveness Shows the Improved Potential of a Recombinant BCG Strain for Bladder Cancer Treatment
por: Rodriguez, Dunia, et al.
Publicado: (2019)

Management of BCG non-responders with fixed dose intravesical gemcitabine in superficial transitional cell carcinoma of urinary bladder
por: Mohanty, N. K., et al.
Publicado: (2008)

Bladder Cancer Immunotherapy: BCG and Beyond
por: Askeland, Eric J., et al.
Publicado: (2012)

Mycobacterium bovis BCG osteoarticular infection complicating immune therapy for bladder cancer: a case report
por: Stern, Rebecca, et al.
Publicado: (2021)

BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer
por: Rouanne, Mathieu, et al.
Publicado: (2022)

CyTOF analysis identifies unusual immune cells in urine of BCG-treated bladder cancer patients
por: Castellano, Eva, et al.
Publicado: (2022)

Intravesical BCG in bladder cancer induces innate immune responses against SARS-CoV-2
por: Pichler, Renate, et al.
Publicado: (2023)

Editorial: Superficial Bladder Cancer
por: Kirkali, Ziya
Publicado: (2006)

Superficial Bladder Cancer Therapy
por: Schenkman, Emmanuel, et al.
Publicado: (2004)

Role of Perioperative Immune Checkpoint Inhibitors in Muscle Invasive Bladder Cancer
por: Chhaya, Saachi, et al.
Publicado: (2023)

A Novel Multistep Iterative Technique for Models in Medical Sciences with Complex Dynamics
por: Qureshi, Sania, et al.
Publicado: (2022)

Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections
por: van Puffelen, Jelmer H, et al.
Publicado: (2023)

Formulation and characterization of EGCG for the treatment of superficial bladder cancer
por: Dettlaff, Katarzyna, et al.
Publicado: (2017)

The Humoral Immune Response to BCG Vaccination
por: Tanner, Rachel, et al.
Publicado: (2019)

From Interferon to Checkpoint Inhibition Therapy—A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette–Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC)
por: Deininger, Susanne, et al.
Publicado: (2022)

Bladder Cancer Exhibiting High Immune Infiltration Shows the Lowest Response Rate to Immune Checkpoint Inhibitors
por: Pan, Shen, et al.
Publicado: (2019)

Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer
por: Lin, Anqi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4rloo8id2jmv9hgklhbssc03sk